TD Cowen Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $23.00

Hims & Hers Health (NYSE:HIMS) had its price objective cut by TD Cowen from $25.00 to $23.00 in a report published on Friday,Benzinga reports. They currently have a hold rating on the stock.

A number of other equities analysts have also weighed in on HIMS. Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and upped their price target for the stock from $12.50 to $23.00 in a research report on Tuesday, March 10th. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a report on Monday, March 9th. Barclays boosted their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $31.71.

Hims & Hers Health Stock Up 0.2%

NYSE HIMS opened at $19.43 on Friday. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $4.43 billion, a P/E ratio of 38.09, a price-to-earnings-growth ratio of 2.34 and a beta of 2.56. The stock’s 50-day moving average price is $21.73 and its 200-day moving average price is $35.70.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 EPS. On average, equities research analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares of the company’s stock, valued at $10,055,792.58. This represents a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares in the company, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 134,984 shares of company stock valued at $3,458,041. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $26,000. Quent Capital LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the third quarter valued at $28,000. Finally, Bogart Wealth LLC increased its position in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Major commercial catalyst — HIMS announced availability of a broad suite of Novo Nordisk FDA‑approved GLP‑1 medications for eligible customers, expanding product mix and potential revenue/ARPU upside from higher‑price branded drugs. Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
• Positive Sentiment: Business model shift — coverage highlights HIMS moving toward a broader mix of branded, FDA‑approved GLP‑1s after the Novo collaboration and FDA shortage resolution, which could lift margins and reduce prior legal/commercial uncertainty. Hims & Hers shifts business model after Novo deal
• Neutral Sentiment: Analyst/features coverage and investor writeups (Seeking Alpha, USA Today sponsored pieces, Yahoo/Fool commentary) are framing a potential reset and longer‑term inflection, useful for context but not immediate proof of sustained upside. Hims & Hers: The Reset Before The Next Inflection
• Neutral Sentiment: Institutional positions remain large (Vanguard, Capital World, Farallon, etc.), which supports liquidity and means any moves could be amplified by institutional flows rather than retail noise. MarketBeat HIMS Coverage
• Negative Sentiment: Fresh analyst pressure — TD Cowen trimmed its price target to $23 and set a “hold”, and other outlets report lower targets/discounted valuations, which can trigger short‑term selling and lower investor conviction. TD Cowen price target cut (Benzinga)
• Negative Sentiment: Legal and governance overhang — a securities‑fraud investigation has been opened (Schall Law Firm), creating regulatory risk that can depress multiples until resolved. Fraud investigation announcement
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold ~9.2k shares recently; continued insider sales have been flagged by analysts and can sap market confidence, especially amid valuation compression. SEC Form 4 — Insider Sale

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.